Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Femasys Inc (NQ: FEMY ) 1.270 -0.060 (-4.51%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 138,216 Open 1.330 Bid (Size) 1.260 (13) Ask (Size) 1.310 (1) Prev. Close 1.330 Today's Range 1.210 - 1.364 52wk Range 0.2479 - 4.750 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives April 18, 2024 From Femasys Inc. Via GlobeNewswire FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 March 28, 2024 FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. Via InvestorPlace Performance YTD +25.74% +25.74% 1 Month -18.06% -18.06% 3 Month +58.77% +58.77% 6 Month -8.63% -8.63% 1 Year +45.98% +45.98% More News Read More Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update March 28, 2024 From Femasys Inc. Via GlobeNewswire Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape March 21, 2024 From Femasys Inc. Via GlobeNewswire Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility March 20, 2024 From Femasys Inc. Via GlobeNewswire Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 March 13, 2024 From Femasys Inc. Via GlobeNewswire Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution March 06, 2024 From Femasys Inc. Via GlobeNewswire Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF February 28, 2024 From Femasys Inc. Via GlobeNewswire First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks February 21, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session February 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session February 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session February 07, 2024 Via Benzinga Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer February 06, 2024 From Femasys Inc. Via GlobeNewswire Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women January 26, 2024 From Femasys Inc. Via GlobeNewswire Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology January 23, 2024 From Femasys Inc. Via GlobeNewswire Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine December 15, 2023 From Femasys Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 14, 2023 Via Benzinga Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer November 30, 2023 From Femasys Inc. Via GlobeNewswire Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch November 28, 2023 From Femasys Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Pre-Market Session November 24, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session November 23, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session November 22, 2023 Via Benzinga PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023 From PharmaCyte Biotech, Inc. Via Business Wire Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech November 15, 2023 From Femasys Inc. Via GlobeNewswire Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update November 14, 2023 From Femasys Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.